問卷

TPIDB > Search Result

Search Result

篩選

List

213Cases

2023-04-10 - 2026-10-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-04-01 - 2026-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2022-02-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-05-02 - 2027-03-22

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2022-09-01 - 2028-12-31

Phase III

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
4Sites

Recruiting4Sites

2022-04-01 - 2029-10-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-09-01 - 2025-04-30

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2025-05-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-06-12 - 2027-05-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

2021-02-19 - 2025-12-31

Phase I

Completed
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CLL
  • Condition/Disease

    Non-Hodgkin Lymphoma/Chronic lymphoid leukemia

  • Test Drug

    JNJ-75348780

Participate Sites
5Sites

Not yet recruiting2Sites

Terminated3Sites